Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods

被引：92
作者：
Kantarjian, Hagop [1 ]
Schiffer, Charles [3 ]
Jones, Dan [2 ]
Cortes, Jorge [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA
[3] Wayne State Univ, Sch Med, Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI USA
来源：
BLOOD | 2008年 / 111卷 / 04期
关键词：
D O I：
10.1182/blood-2007-09-110189
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1774 / 1780
页数：7
相关论文
共 61 条
[1]   Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].
Baccarani, Michele ;
Saglio, Giuseppe ;
Goldman, John ;
Hochhaus, Andreas ;
Simonsson, Bengt ;
Appelbaum, Frederick ;
Apperley, Jane ;
Cervantes, Francisco ;
Cortes, Jorge ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Frangois ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Niederwieser, Dielger ;
Silver, Richard ;
Hehlmann, Rudiger .
BLOOD, 2006, 108 (06) :1809-1820
[2]   Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders [J].
Bonifazi, F ;
de Vivo, A ;
Rosti, G ;
Guilhot, F ;
Guilhot, J ;
Trabacchi, E ;
Hehlmann, R ;
Hochhaus, A ;
Shepherd, PCA ;
Steegmann, JL ;
Kluin-Nelemans, HC ;
Thaler, J ;
Simonsson, B ;
Louwagie, A ;
Reiffers, J ;
Mahon, FX ;
Montefusco, E ;
Alimena, G ;
Hasford, J ;
Richards, S ;
Saglio, G ;
Testoni, N ;
Martinelli, G ;
Tura, S ;
Baccarani, M .
BLOOD, 2001, 98 (10) :3074-3081
[3]   Fluorescence in situ hybridization for the BCR/ABL rearrangement is dependent on the percentage of nonlymphocytic cells in peripheral blood stem cell harvests [J].
Bornhauser, M ;
Mohr, B ;
Ehrenlechner, U ;
Neubauer, A ;
Ehninger, G .
JOURNAL OF HEMATOTHERAPY, 1998, 7 (05) :425-430
[4]   Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations [J].
Bradeen, Heather A. ;
Eide, Christopher A. ;
O'Hare, Thomas ;
Johnson, Kara J. ;
Willis, Stephanie G. ;
Lee, Francis Y. ;
Druker, Brian J. ;
Deininger, Michael W. .
BLOOD, 2006, 108 (07) :2332-2338
[5]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
[6]   Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Parkinson, I ;
Grigg, A ;
Szer, J ;
Taylor, K ;
Herrmann, R ;
Seymour, JF ;
Arthur, C ;
Joske, D ;
Lynch, K ;
Hughes, T .
BLOOD, 2003, 102 (01) :276-283
[7]   Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations [J].
Branford, S ;
Rudzki, Z ;
Parkinson, I ;
Grigg, A ;
Taylor, K ;
Seymour, JF ;
Durrant, S ;
Browett, P ;
Schwarer, AP ;
Arthur, C ;
Catalano, J ;
Leahy, MF ;
Filshie, R ;
Bradstock, K ;
Herrmann, R ;
Joske, D ;
Lynch, K ;
Hughes, T .
BLOOD, 2004, 104 (09) :2926-2932
[8]   Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase [J].
Branford, S ;
Rudzki, Z ;
Harper, A ;
Grigg, A ;
Taylor, K ;
Durrant, S ;
Arthur, C ;
Browett, P ;
Schwarer, AP ;
Ma, D ;
Seymour, JF ;
Bradstock, K ;
Joske, D ;
Lynch, K ;
Gathmann, I ;
Hughes, TP .
LEUKEMIA, 2003, 17 (12) :2401-2409
[9]  
Branford S, 1999, BRIT J HAEMATOL, V107, P587
[10]   Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib [J].
Corbin, AS ;
La Rosée, P ;
Stoffregen, EP ;
Druker, BJ ;
Deininger, MW .
BLOOD, 2003, 101 (11) :4611-4614
1234567